2022
DOI: 10.1016/j.msard.2022.103846
|View full text |Cite
|
Sign up to set email alerts
|

Cerebrospinal fluid amyloid precursor protein as a potential biomarker of fatigue in multiple sclerosis: A pilot study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
0
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 40 publications
0
0
0
Order By: Relevance
“…APP can also be cleaved by β-secretase and γ-secretase to produce the Aβ1-42 peptide and sAPPβ (321)(322)(323)(324)(325), which is a precursor to soluble amyloid-beta. In humans, CSF sAPP is a potential diagnostic biomarker for diseases like Alzheimer's Disease and Multiple Sclerosis (316,320,326), and as a potential predictor of neurodevelopmental outcomes after neonatal GMH-IVH (327,328).…”
Section: Amyloid Precursor Proteinmentioning
confidence: 99%
“…APP can also be cleaved by β-secretase and γ-secretase to produce the Aβ1-42 peptide and sAPPβ (321)(322)(323)(324)(325), which is a precursor to soluble amyloid-beta. In humans, CSF sAPP is a potential diagnostic biomarker for diseases like Alzheimer's Disease and Multiple Sclerosis (316,320,326), and as a potential predictor of neurodevelopmental outcomes after neonatal GMH-IVH (327,328).…”
Section: Amyloid Precursor Proteinmentioning
confidence: 99%
“…The metabolism of APP in pwMS is probably associated with fatigue. APP should be evaluated as a biomarker of the role of structural MS pathology in the development of fatigue in pw MS (Johansson et al, 2022).…”
Section: Amyliod Precursor Protein (App)mentioning
confidence: 99%